101. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- Author
-
Mach, François, Baigent, Colin, Catapano, Alberico L, Koskinas, Konstantinos C, Casula, Manuela, Badimon, Lina, Chapman, M John, De Backer, Guy G, Delgado, Victoria, Ference, Brian A, Graham, Ian M, Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R, Riccardi, Gabriele, Richter, Dimitrios J, Sabatine, Marc S, Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov, Mueller, Christian, Drexel, Heinz, Aboyans, Victor, Corsini, Alberto, Doehner, Wolfram, Farnier, Michel, Gigante, Bruna, Kayikcioglu, Meral, Krstacic, Goran, Lambrinou, Ekaterini, Lewis, Basil S, Masip, Josep, Moulin, Philippe, Petersen, Steffen, Petronio, Anna Sonia, Piepoli, Massimo Francesco, Pintó, Xavier, Räber, Lorenz, Ray, Kausik K, Reiner, Željko, Riesen, Walter F, Roffi, Marco, Schmid, Jean- Paul, Shlyakhto, Evgeny, Simpson, Iain A, Stroes, Erik, Sudano, Isabella, Tselepis, Alexandros D, Viigimaa, Margus, Vindis, Cecile, Vonbank, Alexander, Vrablik, Michal, Vrsalovic, Mislav, Zamorano, José Luis, Collet, Jean- Philippe, John Chapman, M, Windecker, Stephan, Collet, Jean-Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Chris P, Grobbee, Diederick, Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A, Leclercq, Christophe, Lettino, Maddalena, Merkely, Bela, Sousa-Uva, Miguel, Touyz, Rhian M, Nibouche, Djamaleddine, Zelveian, Parounak H, Siostrzonek, Peter, Najafov, Ruslan, van de Borne, Philippe, Pojskic, Belma, Postadzhiyan, Arman, Kypris, Lambros, Špinar, Jindřich, Larsen, Mogens Lytken, Eldin, Hesham Salah, Strandberg, Timo E, Ferrières, Jean, Agladze, Rusudan, Laufs, Ulrich, Rallidis, Loukianos, Bajnok, László, Gudjónsson, Thorbjörn, Maher, Vincent, Henkin, Yaakov, Gulizia, Michele Massimo, Mussagaliyeva, Aisulu, Bajraktari, Gani, Kerimkulova, Alina, Latkovskis, Gustavs, Hamoui, Omar, Slapikas, Rimvydas, Visser, Laurent, Dingli, Philip, Ivanov, Victoria, Boskovic, Aneta, Nazzi, Mbarek, Visseren, Frank, Mitevska, Irena, Retterstøl, Kjetil, Jankowski, Piotr, Fontes-Carvalho, Ricardo, Gaita, Dan, Ezhov, Marat, Foscoli, Marina, Giga, Vojislav, Pella, Daniel, Fras, Zlatko, de Isla, Leopoldo Perez, Hagström, Emil, Lehmann, Roger, Abid, Leila, Ozdogan, Oner, Mitchenko, Olena, Patel, Riyaz S, ESC Scientific Document Group, Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), University of Zurich, and Mach, François
- Subjects
medicine.medical_specialty ,Treatment adherence ,Evinacumab ,[SDV]Life Sciences [q-bio] ,Very low-density lipoproteins ,610 Medicine & health ,Lipoprotein remnants ,030204 cardiovascular system & hematology ,Guidelines ,Total cardiovascular risk ,2705 Cardiology and Cardiovascular Medicine ,Treatment (lifestyle) ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,030212 general & internal medicine ,High-density lipoproteins ,Intensive care medicine ,ComputingMilieux_MISCELLANEOUS ,Dyslipidaemias ,Triglycerides ,Dyslipidemias ,Task force ,business.industry ,Treatment (drugs) ,Lipids ,Coronary heart disease ,3. Good health ,Treatment (adherence) ,Cholesterol ,Cardiovascular Diseases ,Heart Disease Risk Factors ,10209 Clinic for Cardiology ,European atherosclerosis society ,LDL Cholesterol Lipoproteins ,Low-density lipoproteins ,Lipid modification ,Cardiology and Cardiovascular Medicine ,business ,Familial hypercholesterolaemia ,Apolipoprotein B ,All cause mortality ,Guidelines • dyslipidaemias • cholesterol • triglycerides • low-density lipoproteins • high-density lipoproteins • apolipoprotein B • lipoprotein(a) • lipoprotein remnants • total cardiovascular risk • treatment (lifestyle) • treatment (drugs) • treatment (adherence) • very low-density lipoproteins • familial hypercholesterolaemia ,Lipoprotein(a) - Abstract
The previous ESC/EAS lipid Guidelines were published in August 2016. The emergence of a substantial body of evidence over the last few years has required new, up-to-date Guidelines. New evidence has confirmed that the key initiating event in atherogenesis is the retention of low- density lipoprotein (LDL) cholesterol (LDL-C) and other cholesterol-rich apolipoprotein (Apo) B containing lipoproteins within the arterial wall. Several recent placebo-controlled clinical studies have shown that the addition of either ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) to statin therapy provides a further reduction in atherosclerotic cardiovascular disease (ASCVD) risk, which is directly and positively correlated with the incrementally achieved absolute LDL-C reduction. Furthermore, these clinical trials have clearly indicated that the lower the achieved LDL-C values, the lower the risk of future cardiovascular (CV) events, with no lower limit for LDL-C values, or ‘J’-curve effect.
- Published
- 2020
- Full Text
- View/download PDF